MRNA at .43. is it a $50 stock someday? Could happen>>
MRNA specializes in RNA interference (RNAi) which is a system within living cells that helps to control which genes are active and how active they are. In the future, instead of curing disease with drugs, or chemicals, doctors will in a sense go in and turn on or off certain genes to cure a person. MRNA is one of the few public companies that is in this field that is a reasonable buy. Some others are, but they are the big plays like Merck that also have a million other fields of pharma that they are in. MRNA specializes in RNAi.
Here are a few reasons why this could be a $25 stock or higher someday, if it doesn't get bought out first, which knowing the ceo's history, is a very real possibility.
1. This stock was above $3 early last year back when it was strictly a nasal company. It was above $20 3 years ago. It still only has an OS of 31 Million. That is amazing to me that they have barely diluted through this entire downturn in the company's stock value and the economy.
2. They now have a ceo, Michael French, who was solely responsible for the Merck buyout of RNAI (Sirna Ther.) for $1.1 billion 2 years ago at $14/share. He has since moved on to MRNA as CEO and we are just now beginning to see the results of his efforts. Expect a ton more news to come in the very near future. In case you didn't notice, they are assured funding now to continue operations with no dilution after the news Feb 13, and they have no real debt.
3. The hired a CSO on Jan 2 that was in charge of research at Merck and RNAI. That means connections.
4. They have RNAi patents that could be worth billions in the next few years. They have many more patents than the company RNAI ever did and look what happened with that :).
5. The tentative FDA approval in December 08' for their nasal drug allows them to stay on the Nasdaq, partner up with major pharma if need be, and it brings in 10's of millions of dollars a year, and this drug has NOTHING to do with what they do now-it's just a bonus. That means revs to fund RNAi development WITHOUT diluting or financing.
6. As I mentioned, they just got news on Feb 13 of a liscensing agreement with Roche that allows them to continue operations with NO dilutive financing. Next up will be a partnership worth imo hundreds of millions with a big pharma co.
RNAi is a field that most Doctors say will be the way to cure disease by 2012 or so. It has a potential market in the $100's of billions. MRNA is by far the leading publicly traded stock in this field. If RNAI got bought out for $1.1 billion almost 2 years ago, what does that make MRNA worth 2 years from now when their patents are that much closer to actually being used to cure disease? Even $1.1 Billion divided by a 31 M OS is over $36/share.
AI
